Eurofins Bioanalytical Services, a member of Eurofins BioPharma Services, Laboratory Testing division, announces the launch of a Surrogate Virus Neutralization Test (sVNT) antibody assay against the SARS-CoV-2-virus. An alternative to conventional testing with a live virus, this assay is the first neutralizing antibody serology test authorized by the FDA as emergency use authorization (EUA). This innovative assay detects the presence of neutralizing/blocking antibodies against SARS-CoV-2 virus, that block the interaction between the receptor-binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor.
Eurofins Bioanalytical Services expands its technology footprint with the 25 fluorescent channel Novocyte QuanteonTM Flow Cytometer.
Tags: Flow Cytometry
For the 2020 CRO Leadership Awards, Life Science Leader magazine once again teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 60 contract research organizations were assessed on over 20 performance metrics in ISR's annual CRO Quality Benchmarking survey. Eurofins is recognized as a recipient of these awards, exceeding customer expectations in Quality, Capabilities and Compatibility.
Eurofins Bioanalytical Services expands its technology footprint in Flow Cytometry with the addition of Novocyte Quanteon™. The flow cytometer provides an expanded set of capabilities that accommodate today’s high-end and increasingly sophisticated multi-color flow cytometry assays.
In this Bioanalysis Zone interview, David Lanham of Eurofins BioPharma Services discusses flow cytometry for pharmacodynamic biomarker analysis and receptor engagement in early clinical stage work. David also explains the challenges faced when using flow cytometry as an analytical tool, before sharing his thoughts on the progress that has been made to regulate and standardize the field.
The immunogenecity of biologics is a significant concern, which can affect safety and efficacy. In this interview with Dr. Eric Bonner, we explore recent developments in immunogenecity, highlight key challenges when reviewing immunogenecity, and explore current regulations.
Eurofins Bioanalytical Services expands its technology footprint with the addition of Quanterix® SR-X™. The Ultra-Sensitive Biomarker Detection, for the bench-top. Experience the unrivaled power of Simoa® single molecule digital detection technology now available in a compact size with increased workflow flexibility.
Eurofins BioPharma Services is once again excited to sponsor and join over 1,000 professionals at the upcoming 13th WRIB conference in New Orleans from April 1-5, 2019.